Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

This study is currently recruiting participants.

Study NCT00879658 Information provided by Novartis

First Received: April 9, 2009 Last Updated: September 2, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)